加拿大卫生部批准Wegovy降低体重和防止高危成人心脏病发作。 Health Canada approves Wegovy for weight loss and to prevent heart attacks in at-risk adults.

加拿大卫生部批准了Wegovy, Novo Nordisk的减重药物,以减少患有27岁或以上的BMI及现有心血管疾病的成年人患非致命性心脏病的风险。 Health Canada has approved Wegovy, a weight loss drug by Novo Nordisk, to reduce the risk of non-fatal heart attacks in adults with a BMI of 27 or higher and existing cardiovascular disease. 这使Wegovy成为加拿大批准用于肥胖症管理和预防心脏病发作的首例治疗。 This makes Wegovy the first treatment in Canada approved for both obesity management and heart attack prevention. 这种药物 semaglutide 也已在美国、英国和欧盟获得批准用于类似用途。 The drug, semaglutide, has also been approved in the U.S., UK, and EU for similar uses.